Amphstar Acquires Select Injectables From UCBBy
Amphastar Pharmaceuticals, a Rancho Cucamonga, California-based specialty pharmaceutical company, has acquired from UCB Pharma product trademarks and other related product assets, as well as marketing authorizations for 33 products in the UK, Ireland, Australia, and New Zealand, representing 11 different injectable chemical entities, in a deal worth $7.7 million. The acquisition was made through Amphastar's UK subsidiary and UCB Pharma's UK-based International Medication Systems business unit.
The generic injectables products contain the following active ingredients; adrenaline, amiodarone, atropine, calcium chloride, furosemide, glucose, lidocaine, magnesium sulphate, morphine, naloxone, and sodium bicarbonate. Amphastar plans to transfer the products to its facilities in California. The transfer will require the UK Medicines & Healthcare Products Regulatory Agency and other related regulatory agency approval before the products can be re-launched.
Amphastar focuses primarily on developing, manufacturing, marketing, and selling generic and proprietary injectable, inhalation, and intranasal products.